NCT07042204 is a NA clinical trial of Group I (extended platelet-rich fibrin) in Furcation Defects, sponsored by Merna Nasser Mohamed Mostafa Ibrahim Elnahas.

Who is sponsoring NCT07042204?

NCT07042204 is sponsored by Merna Nasser Mohamed Mostafa Ibrahim Elnahas.

What drugs are being tested in NCT07042204?

Interventions in NCT07042204: Group I (extended platelet-rich fibrin), Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin), Group III (bioactive glass nanoparticles and covered by a collagen membrane).

What condition does NCT07042204 study?

NCT07042204 studies Furcation Defects.

Is NCT07042204 still recruiting?

NCT07042204 is currently completed. Last updated 13 January 2026.

Last reviewed 2026-01-13 · How we verify

NCT07042204

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of E-prf Alone and in Combination With Bioactive Glass Nanoparticles in Grade II Furcation Defects

Completed NA Last updated 13 January 2026

What this trial tests

NA trial testing Group I (extended platelet-rich fibrin) in Furcation Defects in 30 participants. Completed in 3 August 2025.

Timeline

3 January 2024

Primary endpoint
3 June 2025

3 August 2025

Quick facts

Lead sponsor	Merna Nasser Mohamed Mostafa Ibrahim Elnahas
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	3 January 2024
Primary completion	3 June 2025
Estimated completion	3 August 2025
Sites	1 location across Egypt

Drugs / interventions tested

Group I (extended platelet-rich fibrin)
Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)
Group III (bioactive glass nanoparticles and covered by a collagen membrane)

Conditions studied

Furcation Defects — all drugs for Furcation Defects →

Sponsor

Merna Nasser Mohamed Mostafa Ibrahim Elnahas

Who can join

Adults 18 to 50, any sex, with Furcation Defects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate and compare the effectiveness of extended platelet-rich fibrin (ePRF) alone and in combination with bioactive glass nanoparticles in the treatment of grade II furcation defects clinically and radiographically.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Furcation Defects

Currently open trials in the same condition.

NCT06270303 — Use of a Bone Substitute Material in the Surgical Therapy of Furcation Defects · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07042204 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merna Nasser Mohamed Mostafa Ibrahim Elnahas
Last refreshed: 13 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07042204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing